Overview

Predict Antidepressant Responsiveness Using Pharmacogenomics

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether genetic information associated with individual depressive symptoms.
Phase:
N/A
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Antidepressive Agents
Fluoxetine
Milnacipran
Mirtazapine
Nortriptyline
Paroxetine
Sertraline
Venlafaxine Hydrochloride